Screener
Zevra Therapeutics, Inc. ZVRA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total assets | $302,712 | $284,731 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $13,962 | $11,598 |
| Current portion of operating lease liabilities | 626 | 419 |
| Current portion of discount and rebate liabilities | 11,777 | 12,188 |
| Current portion of income tax payable | 20,844 | 13,710 |
| Other current liabilities | 1,423 | 1,362 |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s accounts payable?
- Zevra Therapeutics, Inc. (ZVRA) reported accounts payable of $13.96M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s accounts payable changed year-over-year?
- Zevra Therapeutics, Inc.'s accounts payable decreased by 11.9% year-over-year, from $15.84M to $13.96M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s accounts payable has grown at a 11.8% compound annual growth rate (CAGR), from $6.65M to $11.6M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Zevra Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude